Results for T Cells

1 - 10 of 1042

Dr. Gadue studies cell fate decisions, focusing on endoderm and mesoderm specification using human embryonic stem (ES) cells and induced pluripotent stem (iPS).

E-mail:

gaduep [at] chop.edu

Evan Weber, PhD

Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.

E-mail:

weberew [at] chop.edu

Michael S. Marks, PhD

Dr. Marks investigates the molecular mechanisms underlying the formation of cell type-specific lysosome-related organelles; the assembly, delivery and function of their contents; and how these processes are impacted by genetic diseases.

E-mail:

marksms [at] chop.edu

Wei Tong, PhD

Dr. Tong investigates cytokine receptor signaling in normal and neoplastic hematopoietic development. She uses integrated approaches encompassing biochemistry, molecular biology, mouse models, and primary human samples to understand signaling events emanating from cytokine receptors that regulate the development of hematopoietic stem/progenitor cells.

E-mail:

tongw [at] chop.edu

Alexis Thompson

Dr. Thompson is the chief of the Division of Hematology at CHOP and holds the Elias Schwartz, MD, Endowed Chair in Hematology. Her research focuses on sickle cell disease and thalassemia.

E-mail:

thompsona7 [at] chop.edu

Stephan Kadauke, MD, PhD

Dr. Kadauke is the associate director of the Cell and Gene Therapy Laboratory at CHOP and the medical director of the Cell and Gene Therapy Informatics team. His research focuses on developing novel ways to manufacture cell therapies with the goal of accelerating and broadening patient access to these life-saving therapies.

E-mail:

kadaukes [at] chop.edu

Jeffrey D. Roizen, MD, PhD, FAAP

Dr. Roizen's research program aims to understand non-calciometabolic effects of vitamin D and to use this understanding to design new therapeutic approaches to common diseases such as sarcopenia and obesity.

E-mail:

roizenj [at] chop.edu

Leyuan Ma, PhD

Dr. Ma focuses on immune engineering. He leverages genetic, chemistry, and engineering tools to dissect immune cell-cell and cell-tissue crosstalk and harness these crosstalk mechanisms to develop biomaterials, protein, and cell-based precision immunotherapies for cancer and autoimmune diseases.

E-mail:

mal5 [at] chop.edu

Will Bailis, PhD

Dr. Bailis aims to understand how metabolism underlies immunology and disease, by controlling the biochemistry of cells and tissues. His lab does so using in vitro and in vivo CRISPR engineering of primary human and mouse immune cells, with the goal of developing diet and metabolite based therapies.

E-mail:

bailisw [at] chop.edu

Benjamin J. Samelson-Jones, MD, PhD

Dr. Samelson-Jones is a pediatric hematologist dedicated to improving the lives of children with bleeding and clotting disorders. His research focuses on gene therapy for hemophilia, the biochemical basis of coagulation, and the immune responses to hemophilia therapies.

E-mail:

samelsonjonesb [at] chop.edu